News

The European Commission has expanded the indication of Amvuttra (vutrisiran) to include adults with ATTR amyloidosis with cardiomyopathy, or heart damage (ATTR-CM…

In hopes of improving outcomes of amyloidosis, a rare but serious disease caused by the buildup of abnormal amyloid deposits, The College of American Pathologists (…

Kristen Hsu, ARC’s Executive Director of Research, shared the latest updates on ATTR (transthyretin amyloidosis) clinical trials and what these developments mean…

AbstractBACKGROUND:Transthyretin amyloid cardiomyopathy (ATTR-CM) causes a restrictive cardiomyopathy resulting in heart failure (HF). Signaling pathways associated…

Treatments that target the transthyretin (TTR) protein, either by stabilizing it or reducing its production, were associated with about a one-third lower risk of…

Chicago, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The global amyloidosis therapeutics market was valued at 2.95 billion in 2024 and is expected to reach US$ 6.37 billion…

Study OverviewBrief SummaryThis study intends to conduct a prospective observation to investigate the prevalence of cardiac amyloidosis (CA) in patients with aortic…

As per DataM intelligence research report "The global transthyretin amyloid cardiomyopathy (ATTR-CM) was valued at US$ 2.92 Billion n 2023. The global transthyretin…

A new study published in Open Heart provided up-to-date data on the epidemiology of amyloid transthyretin (ATTR) amyloidosis in the US. “Our findings…

AbstractAmyloidosis is a group of disorders caused by extracellular deposition of insoluble fibrillar proteins, leading to progressive organ dysfunction. Cardiac…